CoChat
Sign Up
Cited by 43Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsPeroxisome Proliferator-Activated Receptors

Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus

Open access
Kim, Yoo Mee, Cha, Bong Soo, Kim, Dae Jung, Choi, Sung Hee, Kim, Soo Kyung, Ahn, Chul Woo, Lim, Sung-Kil, Kim, Kyung Rae +2 more·2005·Diabetes Research and Clinical Practice
DOI 10.1016/j.diabres.2004.05.001
Open this paper in CoChat — free account

Abstract

This study evaluated the efficacy of rosiglitazone in non-obese and obese Korean type 2 diabetic patients of long duration. A total of 125 patients (M:F=44:81, mean age: 58.4+/-9.1 years, BMI: 24.2+/-2.7 kg/m2, duration of diabetes: 11.0+/-6.4 years) were randomly allocated to 12 weeks of rosiglitazone treatment (4 mg per day) or a control group. Responders were defined as patients who experienced fasting plasma glucose (FPG) reduction of >20% or HbA1c reduction of >1 (%). Rosiglitazone significantly improved glycemic control by reducing FPG and HbA1c (-3.4 mmol/l and -1.1%, P<0.001, respectively). It also significantly increased HOMA(beta-cell function) (+9.7, P<0.01) and QUICKI (+0.029, P<0.001), and decreased HOMA(IR) (-1.73, P<0.001). Females and those with higher waist-hip ratio made up a greater portion of rosiglitazone-responders. Responders (45 patients, 75%) also showed significantly higher FPG, HbA1c, systolic blood pressures, fasting insulin levels and HOMA(IR), and lower QUICKI than nonresponders. Among these parameters of responders, waist-hip ratio of non-obese subgroup, initial glycemic control of obese subgroup, and systolic blood pressure of both subgroups lost their significance after subdivision analysis. However, the baseline HOMA(IR) and QUICKI were significantly correlated with the response rate to rosiglitazone. Moreover, in multiple logistic regression analysis, HOMA(IR) and QUICKI retained their significance as the independent predictors. Even in Korean type 2 diabetic patients of long duration but with relatively preserved beta-cell function, rosiglitazone improved glycemic control, insulin sensitivity, and beta-cell function. In this ethnic group, female gender, central obesity, and especially severe insulin resistance were identified as predictive clinical parameters of rosiglitazone-responders.

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2004.05.001

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Responders to rosiglitazone were more likely to be females than males.

    “For example, males responded better to sulfonylurea treatment compared with women [80] and responders to rosiglitazone were more likely to be females than males [81].”

    From Sex differences in metabolic homeostasis, diabetes, and obesity (2015) · cites this paper as [81]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kim, Y. M., Cha, B. S., Kim, D. J., Choi, S. H., Kim, S. K., Ahn, C. W., Lim, S.-K., Kim, K. R., Huh, K. B., & Lee, H. C.
Affiliations
  • Yonsei University (KR)
  • Ajou University (KR)
  • National Health Insurance Service Ilsan Hospital (KR)
  • CHA University (KR)
Corresponding author
Lee, Hyun Chul
ORCID
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2005-01
Volume
67
Issue
1
Pages
43-52
ISSN
0168-8227 (ISSN-L)
DOI
10.1016/j.diabres.2004.05.001
OpenAlex
W2019819895
Cited by
43
References
36
Citations by year
2026: 2 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 3
FWCI
1.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
  • YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
  • AJOU Open Repository (Ajou University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
rosiglitazone, type 2 diabetes, predictive biomarkers, treatment response, insulin resistance, HOMA-IR, QUICKI, insulin sensitivity, beta-cell function, fasting blood glucose, HbA1c, waist-to-hip ratio, abdominal obesity, sex differences, Korean patients
MeSH terms
Rosiglitazone, Adult, Blood Glucose, Blood Pressure, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Korea, Male, Middle Aged, Patient Selection, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review